Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last C$0.11 CAD
Change Today 0.00 / 0.00%
Volume 60.2K
VRS On Other Exchanges
Symbol
Exchange
Venture
OTC US
Frankfurt
As of 3:58 PM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).

verisante technology inc (VRS) Snapshot

Open
C$0.11
Previous Close
C$0.11
Day High
C$0.11
Day Low
C$0.11
52 Week High
04/7/14 - C$0.21
52 Week Low
12/17/14 - C$0.08
Market Cap
9.5M
Average Volume 10 Days
49.5K
EPS TTM
C$-0.05
Shares Outstanding
90.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for VERISANTE TECHNOLOGY INC (VRS)

Related News

No related news articles were found.

verisante technology inc (VRS) Related Businessweek News

No Related Businessweek News Found

verisante technology inc (VRS) Details

Verisante Technology, Inc., a medical device company, develops and commercializes skin cancer detection systems. The company’s products include Verisante Aura, a spectroscopy system to aid in the detection of various skin cancers, including basal cell carcinoma, squamous cell carcinoma, melanoma, pre-cancerous lesions, and actinic keratosis; and Verisante Core for the detection of other types of cancer, including lung, gastro-intestinal, colorectal, and cervical cancers. It has a licensing agreement with the BC Cancer Agency for the manufacture, distribution, and sale of products based on patented skin cancer detection technology. The company was formerly known as T-Ray Science Inc. and changed its name to Verisante Technology, Inc. in January 2011. Verisante Technology, Inc. was founded in 2006 and is headquartered in Vancouver, Canada.

Founded in 2006

verisante technology inc (VRS) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

verisante technology inc (VRS) Key Developments

Verisante Technology, Inc. Obtains Mexican Approval to Market and Sell Aura

Verisante Technology, Inc. announced that it has received regulatory approval from the Federal Commission for Protection against Sanitary Risks (COFEPRIS), a division within the Mexican Ministry of Health, to market and sell Aura, a device for the detection of skin cancer, in Mexico. AuraTM is indicated for use for the evaluation of skin lesions that may be clinically suspicious for melanoma, squamous cell carcinoma and/or basal cell carcinoma when a medical professional chooses to obtain additional information before making a final decision to biopsy. Basal cell and squamous cell skin cancers together make up about 96% of all skin cancers. While early detection of melanoma is critical due to its high mortality rate, it is also important to detect the most common skin cancers early in order to achieve the best patient outcomes.

Verisante Technology, Inc. Receives Regulatory Approval from the Federal Commission for Protection Against Sanitary Risks to Market and Sell Aura(TM)

Verisante Technology, Inc. announced that it has received regulatory approval from the Federal Commission for Protection against Sanitary Risks (COFEPRIS), a division within the Mexican Ministry of Health, to market and sell Aura(TM), a device for the detection of skin cancer, in Mexico. While the incidence rate of skin cancer in Latin America is lower than in North America, the mortality rate is generally higher because of the low index of suspicion, which causes diagnosis to be delayed and can result in an advanced presentation of the disease. Aura(TM) is indicated for use for the evaluation of skin lesions that may be clinically suspicious for melanoma, squamous cell carcinoma and/or basal cell carcinoma when a medical professional chooses to obtain additional information before making a final decision to biopsy. Basal cell and squamous cell skin cancers together make up about 96% of all skin cancers. While early detection of melanoma is critical due to its high mortality rate, it is also important to detect the most common skin cancers early in order to achieve the best patient outcomes.

Verisante Technology, Inc. Enters into Collaboration with BC Cancer Agency and Imperial College Healthcare NHS Trust to Develop New Application for its Exclusively Licensed Platform Technology

Verisante Technology, Inc. announced that it has entered into a collaboration with the BC Cancer Agency and Imperial College Healthcare NHS Trust to develop a new application for the company's exclusively licensed platform technology. Imperial College Healthcare NHS Trust will be using Verisante's laser Raman system in a study to determine if the system is able to assist in ascertaining the margins between tumour and normal brain tissue. Verisante is providing Imperial College Healthcare NHS Trust with a Raman system.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VRS:CN C$0.11 CAD 0.00

VRS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Lucid Inc $0.60 USD +0.05
Mauna Kea Technologies €4.97 EUR -0.15
MedX Health Corp C$0.07 CAD 0.00
MELA Sciences Inc $2.99 USD +0.13
Optiscan Imaging Ltd A$0.07 AUD -0.001
View Industry Companies
 

Industry Analysis

VRS

Industry Average

Valuation VRS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 102.9x
Price/Book 2.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 113.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VERISANTE TECHNOLOGY INC, please visit www.verisante.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.